Cure SMA is pleased to announce the participation of scientific leadership in the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (March 13–16, 2022), the American Academy of Neurology (AAN) 2022 Annual Meeting (April 2–7, 2022, and the upcoming Cure SMA Research & Clinical Care Meeting (June 15–17, 2022). Our poster presentations feature data from research […]
Cure SMA is pleased to announce the launch of its first annual State of SMA report. The purpose of this report is to share highlights from Cure SMA’s three databases: the membership database with patient reported outcomes on over 9700 affected individuals worldwide that also includes data from our annual community update survey, the SMA
Check Out Cure SMA’s State of SMA Report Read More »
With today’s newborn screening action by Oregon and New Mexico, Cure SMA has reached a major screening milestone for spinal muscular atrophy (SMA), with 97 percent of all U.S. newborns screened for SMA. Oregon and New Mexico confirmed with Cure SMA that babies born today in their states will now be screening for SMA, making
We are pleased to share a community update on Novartis Gene Therapies’ Clinical Trial Program.
SMA Community Update from Novartis Gene Therapies Read More »
